{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:48:09Z","timestamp":1780404489138,"version":"3.54.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-15-00045"],"award-info":[{"award-number":["AID-OAA-A-15-00045"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.contraception.2024.110490","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:01:04Z","timestamp":1715875264000},"page":"110490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Drug-drug interactions between antiretrovirals and hormonal contraception: An updated systematic review"],"prefix":"10.1016","volume":"138","author":[{"given":"Catherine S.","family":"Todd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Lorenzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamirah","family":"Mussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Ridgeway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Morroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2024.110490_bib1","series-title":"Global HIV statistics \u2013 World AIDS Day Fact Sheet 2023","author":"UNAIDS","year":"2023"},{"issue":"10195","key":"10.1016\/j.contraception.2024.110490_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(19)31288-7","article-title":"HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial","volume":"394","author":"Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2024.110490_bib3","series-title":"Women and HIV: a spotlight on adolescent girls and young women","author":"UNAIDS","year":"2019"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/1966656","article-title":"Fertility reduction and the quality of family planning services","volume":"20","author":"Jain","year":"1989","journal-title":"Stud Fam Plann"},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.9745\/GHSP-D-13-00010","article-title":"Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009","volume":"1","author":"Ross","year":"2013","journal-title":"Glob Health Sci Pract"},{"issue":"11","key":"10.1016\/j.contraception.2024.110490_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2471\/BLT.08.059360","article-title":"Reproductive choices for women with HIV","volume":"87","author":"Wilcher","year":"2009","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.contraception.2024.110490_bib7","series-title":"Contraceptive use by method, 2019: data booklet","author":"United Nations Department of Economic and Social Affairs","year":"2019"},{"key":"10.1016\/j.contraception.2024.110490_bib8","unstructured":"World Health Organization. Medical eligibility criteria for contraceptive use, 5th Edition. Geneva. 2015. Available at: \u3008https:\/\/www.who.int\/publications\/i\/item\/WHO-RHR-15.07\u3009."},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2215\/CJN.02240218","article-title":"Clinical pharmacology in HIV therapy","volume":"14","author":"Atta","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.contraception.2024.110490_bib10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40264-016-0452-7","article-title":"Drug-drug interactions, effectiveness, and safety of hormonal contraceptives in women living with HIV","volume":"39","author":"Scarsi","year":"2016","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1517\/17425255.2013.772579","article-title":"Drug interactions between antiretrovirals and hormonal contraceptives","volume":"9","author":"Tseng","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2010.04.016","article-title":"Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review","volume":"82","author":"Edelman","year":"2010","journal-title":"Contraception"},{"issue":"2-3","key":"10.1016\/j.contraception.2024.110490_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-409X(97)00039-2","article-title":"Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction","volume":"27","author":"Shen","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s13669-020-00289-7","article-title":"Interactions between hormonal contraception and anti-retroviral therapy: an updated review","volume":"9","author":"Krishna","year":"2020","journal-title":"Curr Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.contraception.2024.110490_bib15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/QAD.0000000000001392","article-title":"Drug interactions between hormonal contraceptives and antiretrovirals","volume":"31","author":"Nanda","year":"2017","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.contraception.2024.110490_bib16","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(15)00184-8","article-title":"Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study","volume":"2","author":"Patel","year":"2015","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.contraception.2024.110490_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/cid\/civ1001","article-title":"Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks","volume":"62","author":"Scarsi","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib18","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.1.21396","article-title":"Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines","volume":"20","author":"Patel","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.contraception.2024.110490_bib19","series-title":"FDA approval of HIV medicines","author":"National Institutes of Health","year":"2024"},{"key":"10.1016\/j.contraception.2024.110490_bib20","series-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization","year":"2019"},{"issue":"11","key":"10.1016\/j.contraception.2024.110490_bib21","doi-asserted-by":"crossref","first-page":"e788","DOI":"10.1016\/S2352-3018(19)30238-3","article-title":"Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline","volume":"6","author":"Coelho","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2024.110490_bib22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2024.110490_bib23","series-title":"JBI Manual for evidence synthesis","author":"Aromataris","year":"2020"},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib24","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6113.1000759","article-title":"Correlation between co-therapy of efavirenz-based ART and pregnancy among HIV-positive women on hormonal contraceptive implants at TASO Tororo-Uganda: a retrospective review","volume":"09","author":"Okoboi","year":"2018","journal-title":"J AIDS Clin Res"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.contraception.2019.06.011","article-title":"Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya","volume":"100","author":"Patel","year":"2019","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12916-021-02043-z","article-title":"Pregnancies among women living with HIV using contraceptives and antiretroviral therapy in western Kenya: a retrospective, cohort study","volume":"19","author":"Patel","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.contraception.2024.110490_bib27","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.12688\/gatesopenres.12975.1","article-title":"Contraceptive implant failures among women using antiretroviral therapy in western Kenya: a retrospective cohort study","volume":"3","author":"Pfitzer","year":"2019","journal-title":"Gates Open Res"},{"issue":"9","key":"10.1016\/j.contraception.2024.110490_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26001","article-title":"Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis","volume":"25","author":"Stalter","year":"2022","journal-title":"J Int AIDS Soc"},{"issue":"13","key":"10.1016\/j.contraception.2024.110490_bib29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/QAD.0000000000002308","article-title":"A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda","volume":"33","author":"Patel","year":"2019","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/QAI.0000000000001339","article-title":"Partners in prevention HSV-HIV transmission study and partners PrEP study teams. Hormonal contraception is not associated with reduced ART effectiveness among women initiating ART: evidence from longitudinal data","volume":"75","author":"Patel","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2024.110490_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2023.109975","article-title":"Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: the DoubLNG pharmacokinetic study","volume":"122","author":"Cirrincione","year":"2023","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cpt.667","article-title":"The effect of gene variants on levonorgestrel pharmacokinetics when combined with antiretroviral therapy containing efavirenz or nevirapine","volume":"102","author":"Neary","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2024.110490_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.conx.2020.100027","article-title":"Effect of efavirenz on levonorgestrel concentrations among Malawian levonorgestrel implant users for up to 30\u00a0months of concomitant use: a subanalysis of a randomized clinical trial.","volume":"2","author":"Tang","year":"2020","journal-title":"Contracept X"},{"issue":"14","key":"10.1016\/j.contraception.2024.110490_bib34","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000001591","article-title":"Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy","volume":"31","author":"Chappell","year":"2017","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.contraception.2024.110490_bib35","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/jac\/dkz298","article-title":"Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART","volume":"74","author":"Neary","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"10.1016\/j.contraception.2024.110490_bib36","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/QAD.0000000000003686","article-title":"Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi","volume":"37","author":"Lantz","year":"2023","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00585-22","article-title":"Influence of hormonal contraceptive use and HIV on cervicovaginal cytokines and microbiota in Malawi","volume":"8","author":"Haddad","year":"2023","journal-title":"mSphere"},{"issue":"9","key":"10.1016\/j.contraception.2024.110490_bib38","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1016\/S2352-3018(19)30155-9","article-title":"Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study","volume":"6","author":"Scarsi","year":"2019","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/FPC.0000000000000396","article-title":"Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives","volume":"30","author":"Haas","year":"2020","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.contraception.2019.07.144","article-title":"Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi","volume":"100","author":"Zia","year":"2019","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/cid\/ciz863","article-title":"Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate in African women receiving treatment for human immunodeficiency virus and tuberculosis: potential concern for standard dosing frequency","volume":"71","author":"Mngqibisa","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/cpt.2324","article-title":"A semimechanistic pharmacokinetic model for depot medroxyprogesterone acetate and drug-drug interactions with antiretroviral and antituberculosis treatment","volume":"110","author":"Francis","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/FPC.0000000000000448","article-title":"Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis","volume":"32","author":"Haas","year":"2022","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.contraception.2024.110490_bib44","article-title":"Effect of efavirenz on endogenous progesterone concentrations and contraceptive outcomes among Ugandan HIV infected women co-administering ethinyl estradiol\/levonorgestrel","volume":"2017","author":"Munkwase","year":"2017","journal-title":"AIDS Res Treat"},{"key":"10.1016\/j.contraception.2024.110490_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2023.109951","article-title":"Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens","volume":"121","author":"Scarsi","year":"2023","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2024.110490_bib46","first-page":"126","article-title":"Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis","volume":"33","author":"Agyemang","year":"2023","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02016-18","article-title":"Doravirine and the potential for CYP3A-mediated drug-drug interactions","volume":"63","author":"Khalilieh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib48","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/QAI.0000000000001455","article-title":"Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception","volume":"76","author":"Balkus","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.contraception.2024.110490_bib49","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/jac\/dkac296","article-title":"Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48\u2005weeks with rilpivirine- or darunavir-based antiretroviral therapy","volume":"77","author":"Nakalema","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.contraception.2016.03.003","article-title":"Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial","volume":"94","author":"Nanda","year":"2016","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2024.110490_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199778","article-title":"Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women","volume":"13","author":"Thurman","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-13475-9","article-title":"Genital microbiota of women using a 90-day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya","volume":"12","author":"Dabee","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.contraception.2024.110490_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/frph.2023.1118030","article-title":"Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya","volume":"5","author":"Mugo","year":"2023","journal-title":"Front Reprod Health"},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib54","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1016\/S2214-109X(22)00080-8","article-title":"Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda","volume":"10","author":"Kiweewa Matovu","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"8","key":"10.1016\/j.contraception.2024.110490_bib55","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/cid\/ciz443","volume":"70","author":"Nicol","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib56","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/QAI.0000000000002421","article-title":"Pharmacokinetic and pharmacodynamic impacts of depot medroxyprogesterone acetate use on HIV pre-exposure prophylaxis in women","volume":"85","author":"Tarleton","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAI.0000000000003113","article-title":"Interaction of depot medroxyprogesterone acetate and tenofovir disoproxil fumarate\/emtricitabine on peripheral blood mononuclear cells and cervical tissue susceptibility to HIV infection and pharmacokinetics","volume":"92","author":"Coleman","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/QAI.0000000000001864","article-title":"Effect of hormonal contraception on pharmacokinetics of vaginal tenofovir in healthy women: increased tenofovir diphosphate in injectable depot medroxyprogesterone acetate users","volume":"80","author":"Thurman","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.contraception.2019.06.002","article-title":"Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women","volume":"100","author":"Barcellos","year":"2019","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/QAI.0000000000000997","article-title":"High variability of hormonal levels and no clinically relevant interaction between ethinyl estradiol, desogestrel and lopinavir\/ritonavir in a small sample of HIV-positive adolescents","volume":"72","author":"Kancheva-Landolt","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/13625187.2016.1177718","article-title":"Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir\/ritonavir-based antiretroviral therapy","volume":"21","author":"Ragazini","year":"2016","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2024.110490_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.contraception.2021.08.006","article-title":"Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens","volume":"105","author":"Kreitchmann","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110490_bib63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3851\/IMP3343","article-title":"Confirmation of the drug\u2013drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives","volume":"24","author":"Majeed","year":"2019","journal-title":"Antiviral Therapy"},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/25787489.2019.1638077","article-title":"Pharmacokinetics (PK) of ethinylestradiol\/levonorgestrel co-administered with atazanavir\/cobicistat","volume":"20","author":"Elliot","year":"2019","journal-title":"HIV Res Clin Pract"},{"issue":"7","key":"10.1016\/j.contraception.2024.110490_bib65","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/bcp.13236","article-title":"Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel\/ethinyl oestradiol-containing oral contraceptive in healthy adult women","volume":"83","author":"Trezza","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.contraception.2020.04.019","article-title":"Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy","volume":"102","author":"Bishop","year":"2020","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2024.110490_bib67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/QAI.0000000000002409","article-title":"Hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077","volume":"85","author":"Blair","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.contraception.2024.110490_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25858","article-title":"A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel\/ethinyl estradiol in healthy adult females","volume":"24","author":"Ankrom","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib69","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/hiv.13442","article-title":"Fostemsavir and ethinyl estradiol drug interaction: clinical recommendations for co-administration","volume":"24","author":"Nwokolo","year":"2023","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib70","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/bcp.15051","article-title":"Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women","volume":"88","author":"Pene Dumitrescu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.contraception.2024.110490_bib71","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1089\/aid.2020.0015","article-title":"Effects of depot medroxyprogesterone acetate, copper intrauterine devices, and levonorgestrel implants on early HIV disease progression","volume":"36","author":"Morrison","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003110","article-title":"Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: a randomized controlled trial","volume":"17","author":"Todd","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.contraception.2024.110490_bib73","unstructured":"Yaz (drospirenone\/ ethinyl estradiol). Package insert. Bayer Pharmaceuticals. Revised 2017. Available at: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021676s019lbl.pdf\u3009."},{"key":"10.1016\/j.contraception.2024.110490_bib74","unstructured":"Thurman A. MPT issue: contraceptive efficacy and safety and acceptability of IVR; and current evidence on anti-HSV-2 and anti-HIV IVR activity. Presented at the International AIDS Society Conference 2021, July 21, 2021. Available at: https:\/\/theprogramme.ias2021.org\/PAGMaterial\/PPT\/47_52\/Thurman_IAS_Presentation_28_JUN_2021_FINAL.pdf."},{"key":"10.1016\/j.contraception.2024.110490_bib75","unstructured":"Tybost (cobicistat). Package insert. 2017. Gilead Sciences. Available at: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203094s008lbl.pdf\u3009."},{"issue":"6","key":"10.1016\/j.contraception.2024.110490_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.671","article-title":"Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor","volume":"8","author":"Joshi","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.contraception.2024.110490_bib77","unstructured":"Joanna Briggs Institute. Critical Appraisal Tools, \u3008https:\/\/jbi.global\/critical-appraisal-tools\u3009."},{"issue":"5","key":"10.1016\/j.contraception.2024.110490_bib78","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/QAI.0b013e31827e8f98","article-title":"Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives","volume":"62","author":"Landolt","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2024.110490_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.conx.2022.100073","article-title":"Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate","volume":"4","author":"Taylor","year":"2022","journal-title":"Contracept X"},{"key":"10.1016\/j.contraception.2024.110490_bib80","unstructured":"Kampala Women's Bone Study. Protocol: impact of concurrent initiation of DMPA contraception and tenofovir PrEP on bone loss in young women. Kampala, Uganda; Seattle, Washington, USA; New York, New York, USA; Durham, NC, USA,\u00a02018, \u3008https:\/\/clinicaltrials.gov\/ProvidedDocs\/66\/NCT03464266\/Prot_001.pdf\u3009."},{"key":"10.1016\/j.contraception.2024.110490_bib81","unstructured":"National Institutes of Health. The Kampala Women's Bone Study, 2018. Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03464266\u3009."},{"key":"10.1016\/j.contraception.2024.110490_bib82","unstructured":"National Institutes of Health. Study to assess the effectiveness and safety of lenacapavir for human immunodeficiency virus (HIV) pre-exposure prophylaxis (PURPOSE 2),\u00a02021, \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04925752\u3009."},{"key":"10.1016\/j.contraception.2024.110490_bib83","unstructured":"National Institutes of Health. Study to evaluate the safety and efficacy of lenacapavir in combination with other antiretroviral agents in people living With HIV (CALIBRATE),\u00a02019, \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04143594?term=lenacapavir&draw=2&rank=6\u3009."},{"key":"10.1016\/j.contraception.2024.110490_bib84","unstructured":"National Institutes of Health. Switch to doravirine\/islatravir (DOR\/ISL) in human immunodeficiency virus 1 (HIV-1) participants treated with bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) (MK-8591A-018),\u00a02020, \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04223791?term=islatravir&draw=2&rank=10\u3009."},{"key":"10.1016\/j.contraception.2024.110490_bib85","unstructured":"National Institutes of Health. Randomized, double-blind, efficacy, and safety study of doravirine\/islatravir (DOR\/ISL) in treatment-na\u00efve participants with human immunodeficiency virus type 1 (HIV-1) infection (MK-8591A-020),\u00a02020, \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04233879?term=islatravir&draw=3&rank=11\u3009."},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2024.110490_bib86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/13625180801960012","article-title":"Tolerability and clinical safety of Implanon.","volume":"13","author":"Blumenthal","year":"2008","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"6","key":"10.1016\/j.contraception.2024.110490_bib87","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/ph14060548","article-title":"Safety and benefits of contraceptives implants: a systematic review","volume":"14","author":"Rocca","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.contraception.2024.110490_bib88","doi-asserted-by":"crossref","first-page":"603","DOI":"10.9745\/GHSP-D-18-00093","article-title":"Menstrual bleeding changes are NORMAL: proposed counseling tool to address common reasons for non-use and discontinuation of contraception","volume":"6","author":"Rademacher","year":"2018","journal-title":"Glob Health Sci Pract"},{"issue":"6341","key":"10.1016\/j.contraception.2024.110490_bib89","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.aai9383","article-title":"Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women","volume":"356","author":"Klatt","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib90","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nm.4506","article-title":"Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women","volume":"24","author":"McKinnon","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib91","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1724","article-title":"The effect of atazanavir\/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women","volume":"16","author":"Zhang","year":"2011","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.contraception.2024.110490_bib92","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0b013e3181eb5ff5","article-title":"Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188","volume":"55","author":"Vogler","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2024.110490_bib94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.contraception.2021.12.008","article-title":"Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period","volume":"108","author":"Lazorwitz","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110490_bib95","unstructured":"Patel RC, Stalter RM, Onono M, Brown E, Adeojo L, Adhu C. Dolutegravir-containing ART does not reduce etonogestrel implant concentrations. Conference on Retroviruses and Opportunistic Infections; March 8\u201311, 2020; (Virtual) Boston."},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib96","first-page":"270","article-title":"Recovery of bone mass in women on Depo-Provera and TDF-based art switched to B\/F\/TAF","volume":"31","author":"Kiweewa","year":"2023","journal-title":"Topics Antiviral Med"},{"issue":"2","key":"10.1016\/j.contraception.2024.110490_bib97","first-page":"207","article-title":"Doravirine: safety, tolerability and efficacy in South African women on contraception","volume":"31","author":"Ndlovu","year":"2023","journal-title":"Topics Antiviral Med"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424001628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424001628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:43:41Z","timestamp":1728409421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782424001628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":97,"alternative-id":["S0010782424001628"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110490","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions between antiretrovirals and hormonal contraception: An updated systematic review","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110490"}}